Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
85 Results Found
Integrated CVS-Aetna: What’s at Stake
For the second time in less than a month, the Department of Justice has approved a megamerger between leading players in the health insurance and pharmacy worlds. The DOJ said it will allow the $69 billion merger of CVS Health with Aetna once the insurer sells its Medicare Part D business, which raised concerns about the companies having too much market control.
White House announces deals with Eli Lilly, Novo Nordisk to lower drug costs
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed nations, known as the most-favored-nation price.
Cigna announces new pricing model that would share negotiated discounts with consumers
Cigna’s Evernorth division Oct. 27 announced a new, rebate-free pharmacy benefit model, beginning in 2027, that would reduce monthly prescription drug costs by an average of 30%.
Report finds launch prices for new drugs are significantly higher, exceed inflation
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released Oct. 23 by the Institute for Clinical and Economic Review.
3 Ways Pharma Could Jolt Health Care in 2023
The market for biosimilar drugs to treat cancer, inflammatory diseases, diabetes and more will continue to expand, ideally resulting in lower prices as more pharmaceutical patents expire and competitors enter the market.
Administration announces agreement with Pfizer to lower drug costs
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by other developed nations — wh
AHA urges FTC, DOJ to investigate anticompetitive activity by drug companies on 340B rebate models
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts to impose rebate models within the 340B Drug Pricing Program, saying the actions may violate antitrust laws.
HHS announces access to real-time drug pricing, changes to prior authorization
The Department of Health and Human Services today announced prescription drug reforms
White House announces steps for drug manufacturers to meet ‘most favored nation’ pricing
The Trump administration today
HHS announces new 340B Rebate Model Pilot Program
The Department of Health and Human Services today issued a